DrugPatentWatch Database Preview
Investigational Drug Information for ABX464
Email this page to a colleague
What is the drug development status for ABX464?
ABX464 is an investigational drug.
There have been 16 clinical trials for ABX464.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Ulcer, Colitis, Ulcerative, and Colitis. The leading clinical trial sponsors are Abivax S.A., FLS-RS, and Orion Corporation, Orion Pharma.
There are thirty-five US patents protecting this investigational drug and five hundred and twenty-nine international patents.
Summary for ABX464
| US Patents | 35 |
| International Patents | 529 |
| US Patent Applications | 94 |
| WIPO Patent Applications | 44 |
| Japanese Patent Applications | 49 |
| Clinical Trial Progress | Phase 2 (2020-07-01) |
| Vendors | 22 |
Recent Clinical Trials for ABX464
| Title | Sponsor | Phase |
|---|---|---|
| Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | Abivax S.A. | Phase 2 |
| Safety and Pharmacokinetics Study in Healthy Japanese Volunteers | Abivax S.A. | Phase 1 |
| Evaluaton of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 | Abivax S.A. | Phase 1 |
Clinical Trial Summary for ABX464
Top disease conditions for ABX464
Top clinical trial sponsors for ABX464
US Patents for ABX464
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ABX464 | ⤷ Sign up for a Free Trial | Compounds useful for treating AIDS | ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | ⤷ Sign up for a Free Trial |
| ABX464 | ⤷ Sign up for a Free Trial | Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13A- octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign up for a Free Trial |
| ABX464 | ⤷ Sign up for a Free Trial | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign up for a Free Trial |
| ABX464 | ⤷ Sign up for a Free Trial | Thiocarbamate prodrugs of tofacitinib | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign up for a Free Trial |
| ABX464 | ⤷ Sign up for a Free Trial | Human immunodeficiency virus neutralizing antibodies | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign up for a Free Trial |
| ABX464 | ⤷ Sign up for a Free Trial | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ABX464
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ABX464 | Australia | AU2010258214 | 2029-06-12 | ⤷ Sign up for a Free Trial |
| ABX464 | Australia | AU2010258294 | 2029-06-12 | ⤷ Sign up for a Free Trial |
| ABX464 | Australia | AU2010258295 | 2029-06-12 | ⤷ Sign up for a Free Trial |
| ABX464 | Australia | AU2015203256 | 2029-06-12 | ⤷ Sign up for a Free Trial |
| ABX464 | Australia | AU2017202500 | 2029-06-12 | ⤷ Sign up for a Free Trial |
| ABX464 | Australia | AU2019203896 | 2029-06-12 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
